Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China

Author:

Chen Nan1,Qian Jiaqi2,Chen Jianghua3,Yu Xueqing4,Mei Changlin5,Hao Chuanming6,Jiang Gengru7,Lin Hongli8,Zhang Xinzhou9,Zuo Li10,He Qiang11,Fu Ping12,Li Xuemei13,Ni Dalvin14,Hemmerich Stefan14,Liu Cameron14,Szczech Lynda14,Besarab Anatole14,Neff Thomas B.14,Peony Yu Kin-Hung14,Valone Frank H.14

Affiliation:

1. Institute of Nephrology, Department of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

2. Renji Hospital, Shanghai, China

3. Zhejiang University, Hangzhou, China

4. Sun Yat-Sen University, Guangzhou, China

5. Changzheng Hospital, Shanghai, China

6. Shanghai Huashan Hospital, Shanghai, China

7. Xinhua Hospital, Jiaotong University, Shanghai, China

8. Dalian Medical University, Dalian, China

9. Shenzhen People’s Hospital, Shenzhen, China

10. Beijing University First Hospital, Beijing, China

11. Sichuan Province Hospital, Chengdu, China

12. West China Hospital, Chengdu, China

13. Union Medical College Hospital, Beijing, China

14. FibroGen, Inc., San Francisco, CA, USA

Publisher

Oxford University Press (OUP)

Subject

Transplantation,Nephrology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3